• Our Vision is to improve healthcare as a global provider of innovative and reliable diagnostic tests.
  • Our Mission is to identify and develop novel patentable diagnostic markers and technologies which can be commercialised to meet clinical needs.
  • We will collaborate with partners, create branded products and identify complementary businesses which support our objective of continuing to grow as a respected and profitable healthcare company.
  • Our Values include meeting all current and future regulatory, quality and environmental standards appropriate for our industry and the countries in which we operate.

Rheumatoid Arthritis (RA) is a common, systemic autoimmune disease affecting between 0.5-1% of the adult population. Axis-Shield offers a definitive test for early detection of this debilitating disease through the measurement of antibodies to cyclic citrullinated peptides (anti-CCP).


RA is characterised by inflammation of the synovial joints. This can lead to progressive joint destruction and consequently impair the quality of life.

It is generally accepted that early intervention is vital in preventing irreversible joint damage and therefore it is important to diagnose RA as early in the disease course as possible.  

New classification criteria for rheumatoid arthritis (RA) were published in 2010. The revised criteria have been approved by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR). These new RA classification criteria follow recommendations at the 2009 ACR Congress and will allow clinicians to focus on the important need for earlier diagnosis and more effective early therapeutic intervention. The outcome of the new criteria means that ACPA (principally anti-CCP antibodies) testing has been added to the biochemical criteria for disease classification, in addition to the long established sole blood test, the relatively non-specific Rheumatoid Factor assay.


This formally recognised the importance of testing for anti-CCP antibodies in the early detection of rheumatoid arthritis from the major global authorities on this potentially debilitating disease. Anti-CCP is a key marker for Axis-Shield and this inclusion reinforces the importance of protecting our IP on anti-CCP testing.



For more details on our Anti-CCP assay, please visit the Anti-CCP page.

Axis-Shield at a Glance

A pioneering organisation focused on the development and manufacturing of important and innovative in vitro diagnostic tests for use in clinical laboratories.

› More about our tests

Focus on Homocysteine

As a general marker of overall health status, few tests carry greater predictive weight than Homocysteine. The amount of Homocysteine in your blood is one of the best independent indicators of how healthy you are.


› Axis-Shield Homocysteine assays

© Axis-Shield plc 2011. All rights reserved. Registered in Scotland No. SC145200 - Sitemap | Terms-of-Use | Accessibility | Disclaimer
Luna Place, The Technology Park, Dundee, DD2 1XA, Scotland.
Diagnostics for the laboratory & the point of care in areas of clinical need including diabetes, cardiovascular & neurodegenerative disease, rheumatoid arthritis & infectious disease.